FinTagging
Collection
17 items
•
Updated
context
stringlengths 21
33.9k
| category
stringclasses 2
values | entity
stringlengths 1
12
| entity_type
stringclasses 5
values | query
stringlengths 97
3.31k
| answer
stringlengths 12
169
|
|---|---|---|---|---|---|
(a) Series C, $ 0.70252 per share; Series D, $ 0.95613 per share; Series E, $ 1.46875 per share; and Series F, $ 1.40625 per share.
|
text
|
0.70252
|
perShareItemType
|
text: <entity> 0.70252 </entity> <entity type> perShareItemType </entity type> <context> (a) Series C, $ 0.70252 per share; Series D, $ 0.95613 per share; Series E, $ 1.46875 per share; and Series F, $ 1.40625 per share. </context>
|
us-gaap:PreferredStockDividendsPerShareCashPaid
|
(a) Series C, $ 0.70252 per share; Series D, $ 0.95613 per share; Series E, $ 1.46875 per share; and Series F, $ 1.40625 per share.
|
text
|
0.95613
|
perShareItemType
|
text: <entity> 0.95613 </entity> <entity type> perShareItemType </entity type> <context> (a) Series C, $ 0.70252 per share; Series D, $ 0.95613 per share; Series E, $ 1.46875 per share; and Series F, $ 1.40625 per share. </context>
|
us-gaap:PreferredStockDividendsPerShareCashPaid
|
(a) Series C, $ 0.70252 per share; Series D, $ 0.95613 per share; Series E, $ 1.46875 per share; and Series F, $ 1.40625 per share.
|
text
|
1.46875
|
perShareItemType
|
text: <entity> 1.46875 </entity> <entity type> perShareItemType </entity type> <context> (a) Series C, $ 0.70252 per share; Series D, $ 0.95613 per share; Series E, $ 1.46875 per share; and Series F, $ 1.40625 per share. </context>
|
us-gaap:PreferredStockDividendsPerShareCashPaid
|
(a) Series C, $ 0.70252 per share; Series D, $ 0.95613 per share; Series E, $ 1.46875 per share; and Series F, $ 1.40625 per share.
|
text
|
1.40625
|
perShareItemType
|
text: <entity> 1.40625 </entity> <entity type> perShareItemType </entity type> <context> (a) Series C, $ 0.70252 per share; Series D, $ 0.95613 per share; Series E, $ 1.46875 per share; and Series F, $ 1.40625 per share. </context>
|
us-gaap:PreferredStockDividendsPerShareCashPaid
|
The fair value of restricted common stock awards is their fair market value on the date of grant. Performance awards are based on performance goals of earnings per share and total shareholder return, with vesting ranging from a minimum of 0 % to a maximum of 150 % of the target award. Performance awards are valued utilizing a Monte Carlo simulation model to estimate fair value of the awards at the grant date. The fair values of stock options and restricted stock awards are amortized as compensation expense on a straight-line basis over the vesting period of the grants. Expenses related to stock options and restricted stock awards are fully recognized on the date the colleague meets the definition of normal or early retirement. Compensation expense recognized is included in personnel expense on the consolidated statements of income. See Note 11 for additional information on stock-based compensation.
|
text
|
0
|
percentItemType
|
text: <entity> 0 </entity> <entity type> percentItemType </entity type> <context> The fair value of restricted common stock awards is their fair market value on the date of grant. Performance awards are based on performance goals of earnings per share and total shareholder return, with vesting ranging from a minimum of 0 % to a maximum of 150 % of the target award. Performance awards are valued utilizing a Monte Carlo simulation model to estimate fair value of the awards at the grant date. The fair values of stock options and restricted stock awards are amortized as compensation expense on a straight-line basis over the vesting period of the grants. Expenses related to stock options and restricted stock awards are fully recognized on the date the colleague meets the definition of normal or early retirement. Compensation expense recognized is included in personnel expense on the consolidated statements of income. See Note 11 for additional information on stock-based compensation. </context>
|
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
|
The fair value of restricted common stock awards is their fair market value on the date of grant. Performance awards are based on performance goals of earnings per share and total shareholder return, with vesting ranging from a minimum of 0 % to a maximum of 150 % of the target award. Performance awards are valued utilizing a Monte Carlo simulation model to estimate fair value of the awards at the grant date. The fair values of stock options and restricted stock awards are amortized as compensation expense on a straight-line basis over the vesting period of the grants. Expenses related to stock options and restricted stock awards are fully recognized on the date the colleague meets the definition of normal or early retirement. Compensation expense recognized is included in personnel expense on the consolidated statements of income. See Note 11 for additional information on stock-based compensation.
|
text
|
150
|
percentItemType
|
text: <entity> 150 </entity> <entity type> percentItemType </entity type> <context> The fair value of restricted common stock awards is their fair market value on the date of grant. Performance awards are based on performance goals of earnings per share and total shareholder return, with vesting ranging from a minimum of 0 % to a maximum of 150 % of the target award. Performance awards are valued utilizing a Monte Carlo simulation model to estimate fair value of the awards at the grant date. The fair values of stock options and restricted stock awards are amortized as compensation expense on a straight-line basis over the vesting period of the grants. Expenses related to stock options and restricted stock awards are fully recognized on the date the colleague meets the definition of normal or early retirement. Compensation expense recognized is included in personnel expense on the consolidated statements of income. See Note 11 for additional information on stock-based compensation. </context>
|
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
|
On March 1, 2021, the Corporation completed the sale of its wealth management subsidiary, Whitnell, to Rockefeller for a purchase price of $ 8 million. The Corporation reported a first quarter 2021 pre-tax gain of $ 2 million, included in asset gains, net on the consolidated statements of income, in conjunction with the sale.
|
text
|
8
|
monetaryItemType
|
text: <entity> 8 </entity> <entity type> monetaryItemType </entity type> <context> On March 1, 2021, the Corporation completed the sale of its wealth management subsidiary, Whitnell, to Rockefeller for a purchase price of $ 8 million. The Corporation reported a first quarter 2021 pre-tax gain of $ 2 million, included in asset gains, net on the consolidated statements of income, in conjunction with the sale. </context>
|
us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
|
During the fourth quarter of 2023, the Corporation sold lower yielding AFS securities with a carrying value of $ 715 million at a net loss of $ 65 million and reinvested the proceeds in higher yielding and lower risk-weighted GNMA securities. Additionally, during the fourth quarter of 2023, the Corporation sold 1,000 shares of its Visa Class B restricted shares and wrote up its remaining shares based on that market price, resulting in a gain of $ 6 million.
|
text
|
715
|
monetaryItemType
|
text: <entity> 715 </entity> <entity type> monetaryItemType </entity type> <context> During the fourth quarter of 2023, the Corporation sold lower yielding AFS securities with a carrying value of $ 715 million at a net loss of $ 65 million and reinvested the proceeds in higher yielding and lower risk-weighted GNMA securities. Additionally, during the fourth quarter of 2023, the Corporation sold 1,000 shares of its Visa Class B restricted shares and wrote up its remaining shares based on that market price, resulting in a gain of $ 6 million. </context>
|
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
During the fourth quarter of 2023, the Corporation sold lower yielding AFS securities with a carrying value of $ 715 million at a net loss of $ 65 million and reinvested the proceeds in higher yielding and lower risk-weighted GNMA securities. Additionally, during the fourth quarter of 2023, the Corporation sold 1,000 shares of its Visa Class B restricted shares and wrote up its remaining shares based on that market price, resulting in a gain of $ 6 million.
|
text
|
65
|
monetaryItemType
|
text: <entity> 65 </entity> <entity type> monetaryItemType </entity type> <context> During the fourth quarter of 2023, the Corporation sold lower yielding AFS securities with a carrying value of $ 715 million at a net loss of $ 65 million and reinvested the proceeds in higher yielding and lower risk-weighted GNMA securities. Additionally, during the fourth quarter of 2023, the Corporation sold 1,000 shares of its Visa Class B restricted shares and wrote up its remaining shares based on that market price, resulting in a gain of $ 6 million. </context>
|
us-gaap:GainLossOnSaleOfInvestments
|
During the fourth quarter of 2023, the Corporation sold lower yielding AFS securities with a carrying value of $ 715 million at a net loss of $ 65 million and reinvested the proceeds in higher yielding and lower risk-weighted GNMA securities. Additionally, during the fourth quarter of 2023, the Corporation sold 1,000 shares of its Visa Class B restricted shares and wrote up its remaining shares based on that market price, resulting in a gain of $ 6 million.
|
text
|
6
|
monetaryItemType
|
text: <entity> 6 </entity> <entity type> monetaryItemType </entity type> <context> During the fourth quarter of 2023, the Corporation sold lower yielding AFS securities with a carrying value of $ 715 million at a net loss of $ 65 million and reinvested the proceeds in higher yielding and lower risk-weighted GNMA securities. Additionally, during the fourth quarter of 2023, the Corporation sold 1,000 shares of its Visa Class B restricted shares and wrote up its remaining shares based on that market price, resulting in a gain of $ 6 million. </context>
|
us-gaap:GainLossOnSaleOfInvestments
|
During the fourth quarter of 2022, the Corporation sold $ 110 million of lower yielding municipal securities at a loss of $ 2 million and reinvested the proceeds into higher yielding and lower risk-weighted GNMA securities. During the third quarter of 2022, the Corporation sold its Visa Class B restricted shares obtained in the acquisition of First Staunton, which were carried at a zero-cost basis. The remaining shares of Visa Class B restricted shares held by the Corporation, which are carried at fair value, were subsequently written up to reflect the new observable price resulting from that sale.
|
text
|
110
|
monetaryItemType
|
text: <entity> 110 </entity> <entity type> monetaryItemType </entity type> <context> During the fourth quarter of 2022, the Corporation sold $ 110 million of lower yielding municipal securities at a loss of $ 2 million and reinvested the proceeds into higher yielding and lower risk-weighted GNMA securities. During the third quarter of 2022, the Corporation sold its Visa Class B restricted shares obtained in the acquisition of First Staunton, which were carried at a zero-cost basis. The remaining shares of Visa Class B restricted shares held by the Corporation, which are carried at fair value, were subsequently written up to reflect the new observable price resulting from that sale. </context>
|
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
During the fourth quarter of 2022, the Corporation sold $ 110 million of lower yielding municipal securities at a loss of $ 2 million and reinvested the proceeds into higher yielding and lower risk-weighted GNMA securities. During the third quarter of 2022, the Corporation sold its Visa Class B restricted shares obtained in the acquisition of First Staunton, which were carried at a zero-cost basis. The remaining shares of Visa Class B restricted shares held by the Corporation, which are carried at fair value, were subsequently written up to reflect the new observable price resulting from that sale.
|
text
|
2
|
monetaryItemType
|
text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> During the fourth quarter of 2022, the Corporation sold $ 110 million of lower yielding municipal securities at a loss of $ 2 million and reinvested the proceeds into higher yielding and lower risk-weighted GNMA securities. During the third quarter of 2022, the Corporation sold its Visa Class B restricted shares obtained in the acquisition of First Staunton, which were carried at a zero-cost basis. The remaining shares of Visa Class B restricted shares held by the Corporation, which are carried at fair value, were subsequently written up to reflect the new observable price resulting from that sale. </context>
|
us-gaap:GainLossOnSaleOfInvestments
|
During the second quarter of 2021, the Corporation sold $ 107 million of lower yielding FFELP student loan asset backed securities at an immaterial gain and reinvested the proceeds into higher yielding MBS. During the first quarter of 2021, the Corporation sold $ 51 million of lower yielding U.S. Treasury and Agency securities at an immaterial loss to take advantage of the steeper yield curve by reinvesting the proceeds into similar but higher yielding, longer duration securities.
|
text
|
107
|
monetaryItemType
|
text: <entity> 107 </entity> <entity type> monetaryItemType </entity type> <context> During the second quarter of 2021, the Corporation sold $ 107 million of lower yielding FFELP student loan asset backed securities at an immaterial gain and reinvested the proceeds into higher yielding MBS. During the first quarter of 2021, the Corporation sold $ 51 million of lower yielding U.S. Treasury and Agency securities at an immaterial loss to take advantage of the steeper yield curve by reinvesting the proceeds into similar but higher yielding, longer duration securities. </context>
|
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
During the second quarter of 2021, the Corporation sold $ 107 million of lower yielding FFELP student loan asset backed securities at an immaterial gain and reinvested the proceeds into higher yielding MBS. During the first quarter of 2021, the Corporation sold $ 51 million of lower yielding U.S. Treasury and Agency securities at an immaterial loss to take advantage of the steeper yield curve by reinvesting the proceeds into similar but higher yielding, longer duration securities.
|
text
|
51
|
monetaryItemType
|
text: <entity> 51 </entity> <entity type> monetaryItemType </entity type> <context> During the second quarter of 2021, the Corporation sold $ 107 million of lower yielding FFELP student loan asset backed securities at an immaterial gain and reinvested the proceeds into higher yielding MBS. During the first quarter of 2021, the Corporation sold $ 51 million of lower yielding U.S. Treasury and Agency securities at an immaterial loss to take advantage of the steeper yield curve by reinvesting the proceeds into similar but higher yielding, longer duration securities. </context>
|
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
|
Investment securities with a carrying value of $ 1.6 billion at December 31, 2023 and $ 2.3 billion at December 31, 2022 were pledged as required to secure certain deposits or for other purposes.
|
text
|
1.6
|
monetaryItemType
|
text: <entity> 1.6 </entity> <entity type> monetaryItemType </entity type> <context> Investment securities with a carrying value of $ 1.6 billion at December 31, 2023 and $ 2.3 billion at December 31, 2022 were pledged as required to secure certain deposits or for other purposes. </context>
|
us-gaap:DebtInstrumentCollateralAmount
|
Investment securities with a carrying value of $ 1.6 billion at December 31, 2023 and $ 2.3 billion at December 31, 2022 were pledged as required to secure certain deposits or for other purposes.
|
text
|
2.3
|
monetaryItemType
|
text: <entity> 2.3 </entity> <entity type> monetaryItemType </entity type> <context> Investment securities with a carrying value of $ 1.6 billion at December 31, 2023 and $ 2.3 billion at December 31, 2022 were pledged as required to secure certain deposits or for other purposes. </context>
|
us-gaap:DebtInstrumentCollateralAmount
|
Accrued interest receivable on HTM securities totaled $ 18 million and $ 19 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on AFS securities totaled $ 15 million and $ 9 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on both HTM and AFS securities is included in interest receivable on the consolidated balance sheets. There was no interest income reversed for investments going into nonaccrual for the years ended December 31, 2023 and 2022.
|
text
|
18
|
monetaryItemType
|
text: <entity> 18 </entity> <entity type> monetaryItemType </entity type> <context> Accrued interest receivable on HTM securities totaled $ 18 million and $ 19 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on AFS securities totaled $ 15 million and $ 9 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on both HTM and AFS securities is included in interest receivable on the consolidated balance sheets. There was no interest income reversed for investments going into nonaccrual for the years ended December 31, 2023 and 2022. </context>
|
us-gaap:InterestReceivable
|
Accrued interest receivable on HTM securities totaled $ 18 million and $ 19 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on AFS securities totaled $ 15 million and $ 9 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on both HTM and AFS securities is included in interest receivable on the consolidated balance sheets. There was no interest income reversed for investments going into nonaccrual for the years ended December 31, 2023 and 2022.
|
text
|
19
|
monetaryItemType
|
text: <entity> 19 </entity> <entity type> monetaryItemType </entity type> <context> Accrued interest receivable on HTM securities totaled $ 18 million and $ 19 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on AFS securities totaled $ 15 million and $ 9 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on both HTM and AFS securities is included in interest receivable on the consolidated balance sheets. There was no interest income reversed for investments going into nonaccrual for the years ended December 31, 2023 and 2022. </context>
|
us-gaap:InterestReceivable
|
Accrued interest receivable on HTM securities totaled $ 18 million and $ 19 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on AFS securities totaled $ 15 million and $ 9 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on both HTM and AFS securities is included in interest receivable on the consolidated balance sheets. There was no interest income reversed for investments going into nonaccrual for the years ended December 31, 2023 and 2022.
|
text
|
15
|
monetaryItemType
|
text: <entity> 15 </entity> <entity type> monetaryItemType </entity type> <context> Accrued interest receivable on HTM securities totaled $ 18 million and $ 19 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on AFS securities totaled $ 15 million and $ 9 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on both HTM and AFS securities is included in interest receivable on the consolidated balance sheets. There was no interest income reversed for investments going into nonaccrual for the years ended December 31, 2023 and 2022. </context>
|
us-gaap:InterestReceivable
|
Accrued interest receivable on HTM securities totaled $ 18 million and $ 19 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on AFS securities totaled $ 15 million and $ 9 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on both HTM and AFS securities is included in interest receivable on the consolidated balance sheets. There was no interest income reversed for investments going into nonaccrual for the years ended December 31, 2023 and 2022.
|
text
|
9
|
monetaryItemType
|
text: <entity> 9 </entity> <entity type> monetaryItemType </entity type> <context> Accrued interest receivable on HTM securities totaled $ 18 million and $ 19 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on AFS securities totaled $ 15 million and $ 9 million at December 31, 2023 and 2022, respectively. Accrued interest receivable on both HTM and AFS securities is included in interest receivable on the consolidated balance sheets. There was no interest income reversed for investments going into nonaccrual for the years ended December 31, 2023 and 2022. </context>
|
us-gaap:InterestReceivable
|
The allowance for credit losses on HTM securities was approximately $ 75 ,000 and $ 54 ,000 at December 31, 2023 and 2022, respectively, attributable entirely to the Corporation's municipal securities, included in HTM investment securities, net, at amortized cost on the consolidated balance sheets. The Corporation also holds U.S. Treasury, municipal, and mortgage-related securities issued by the U.S. government or a GSE which are backed by the full faith and credit of the U.S. government and private-label residential mortgage-related securities that have credit enhancement which covers the first 15% of losses and, as a result, no allowance for credit losses has been recorded related to these securities.
|
text
|
75
|
monetaryItemType
|
text: <entity> 75 </entity> <entity type> monetaryItemType </entity type> <context> The allowance for credit losses on HTM securities was approximately $ 75 ,000 and $ 54 ,000 at December 31, 2023 and 2022, respectively, attributable entirely to the Corporation's municipal securities, included in HTM investment securities, net, at amortized cost on the consolidated balance sheets. The Corporation also holds U.S. Treasury, municipal, and mortgage-related securities issued by the U.S. government or a GSE which are backed by the full faith and credit of the U.S. government and private-label residential mortgage-related securities that have credit enhancement which covers the first 15% of losses and, as a result, no allowance for credit losses has been recorded related to these securities. </context>
|
us-gaap:DebtSecuritiesHeldToMaturityAllowanceForCreditLoss
|
The allowance for credit losses on HTM securities was approximately $ 75 ,000 and $ 54 ,000 at December 31, 2023 and 2022, respectively, attributable entirely to the Corporation's municipal securities, included in HTM investment securities, net, at amortized cost on the consolidated balance sheets. The Corporation also holds U.S. Treasury, municipal, and mortgage-related securities issued by the U.S. government or a GSE which are backed by the full faith and credit of the U.S. government and private-label residential mortgage-related securities that have credit enhancement which covers the first 15% of losses and, as a result, no allowance for credit losses has been recorded related to these securities.
|
text
|
54
|
monetaryItemType
|
text: <entity> 54 </entity> <entity type> monetaryItemType </entity type> <context> The allowance for credit losses on HTM securities was approximately $ 75 ,000 and $ 54 ,000 at December 31, 2023 and 2022, respectively, attributable entirely to the Corporation's municipal securities, included in HTM investment securities, net, at amortized cost on the consolidated balance sheets. The Corporation also holds U.S. Treasury, municipal, and mortgage-related securities issued by the U.S. government or a GSE which are backed by the full faith and credit of the U.S. government and private-label residential mortgage-related securities that have credit enhancement which covers the first 15% of losses and, as a result, no allowance for credit losses has been recorded related to these securities. </context>
|
us-gaap:DebtSecuritiesHeldToMaturityAllowanceForCreditLoss
|
The Corporation is required to maintain Federal Reserve Bank stock and FHLB stock as a member bank of both the Federal Reserve System and the FHLB, and in amounts as required by these institutions. These equity securities are “restricted” in that they can only be sold back to the respective institutions or another member institution at par. Therefore, they are less liquid than other marketable equity securities and their fair value is equal to amortized cost. The Corporation had FHLB stock of $ 143 million and $ 209 million at December 31, 2023 and 2022, respectively. The Corporation had Federal Reserve Bank stock of $ 87 million at both December 31, 2023 and 2022. Accrued interest receivable on FHLB stock totaled $ 4 million and $ 3 million at December 31, 2023 and 2022, respectively. There was no accrued interest receivable on Federal Reserve Bank stock at both December 31, 2023 and December 31, 2022. Accrued interest receivable on both FHLB stock and Federal Reserve Bank stock is included in interest receivable on the consolidated balance sheets.
|
text
|
143
|
monetaryItemType
|
text: <entity> 143 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation is required to maintain Federal Reserve Bank stock and FHLB stock as a member bank of both the Federal Reserve System and the FHLB, and in amounts as required by these institutions. These equity securities are “restricted” in that they can only be sold back to the respective institutions or another member institution at par. Therefore, they are less liquid than other marketable equity securities and their fair value is equal to amortized cost. The Corporation had FHLB stock of $ 143 million and $ 209 million at December 31, 2023 and 2022, respectively. The Corporation had Federal Reserve Bank stock of $ 87 million at both December 31, 2023 and 2022. Accrued interest receivable on FHLB stock totaled $ 4 million and $ 3 million at December 31, 2023 and 2022, respectively. There was no accrued interest receivable on Federal Reserve Bank stock at both December 31, 2023 and December 31, 2022. Accrued interest receivable on both FHLB stock and Federal Reserve Bank stock is included in interest receivable on the consolidated balance sheets. </context>
|
us-gaap:FederalHomeLoanBankStock
|
The Corporation is required to maintain Federal Reserve Bank stock and FHLB stock as a member bank of both the Federal Reserve System and the FHLB, and in amounts as required by these institutions. These equity securities are “restricted” in that they can only be sold back to the respective institutions or another member institution at par. Therefore, they are less liquid than other marketable equity securities and their fair value is equal to amortized cost. The Corporation had FHLB stock of $ 143 million and $ 209 million at December 31, 2023 and 2022, respectively. The Corporation had Federal Reserve Bank stock of $ 87 million at both December 31, 2023 and 2022. Accrued interest receivable on FHLB stock totaled $ 4 million and $ 3 million at December 31, 2023 and 2022, respectively. There was no accrued interest receivable on Federal Reserve Bank stock at both December 31, 2023 and December 31, 2022. Accrued interest receivable on both FHLB stock and Federal Reserve Bank stock is included in interest receivable on the consolidated balance sheets.
|
text
|
209
|
monetaryItemType
|
text: <entity> 209 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation is required to maintain Federal Reserve Bank stock and FHLB stock as a member bank of both the Federal Reserve System and the FHLB, and in amounts as required by these institutions. These equity securities are “restricted” in that they can only be sold back to the respective institutions or another member institution at par. Therefore, they are less liquid than other marketable equity securities and their fair value is equal to amortized cost. The Corporation had FHLB stock of $ 143 million and $ 209 million at December 31, 2023 and 2022, respectively. The Corporation had Federal Reserve Bank stock of $ 87 million at both December 31, 2023 and 2022. Accrued interest receivable on FHLB stock totaled $ 4 million and $ 3 million at December 31, 2023 and 2022, respectively. There was no accrued interest receivable on Federal Reserve Bank stock at both December 31, 2023 and December 31, 2022. Accrued interest receivable on both FHLB stock and Federal Reserve Bank stock is included in interest receivable on the consolidated balance sheets. </context>
|
us-gaap:FederalHomeLoanBankStock
|
The Corporation is required to maintain Federal Reserve Bank stock and FHLB stock as a member bank of both the Federal Reserve System and the FHLB, and in amounts as required by these institutions. These equity securities are “restricted” in that they can only be sold back to the respective institutions or another member institution at par. Therefore, they are less liquid than other marketable equity securities and their fair value is equal to amortized cost. The Corporation had FHLB stock of $ 143 million and $ 209 million at December 31, 2023 and 2022, respectively. The Corporation had Federal Reserve Bank stock of $ 87 million at both December 31, 2023 and 2022. Accrued interest receivable on FHLB stock totaled $ 4 million and $ 3 million at December 31, 2023 and 2022, respectively. There was no accrued interest receivable on Federal Reserve Bank stock at both December 31, 2023 and December 31, 2022. Accrued interest receivable on both FHLB stock and Federal Reserve Bank stock is included in interest receivable on the consolidated balance sheets.
|
text
|
4
|
monetaryItemType
|
text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation is required to maintain Federal Reserve Bank stock and FHLB stock as a member bank of both the Federal Reserve System and the FHLB, and in amounts as required by these institutions. These equity securities are “restricted” in that they can only be sold back to the respective institutions or another member institution at par. Therefore, they are less liquid than other marketable equity securities and their fair value is equal to amortized cost. The Corporation had FHLB stock of $ 143 million and $ 209 million at December 31, 2023 and 2022, respectively. The Corporation had Federal Reserve Bank stock of $ 87 million at both December 31, 2023 and 2022. Accrued interest receivable on FHLB stock totaled $ 4 million and $ 3 million at December 31, 2023 and 2022, respectively. There was no accrued interest receivable on Federal Reserve Bank stock at both December 31, 2023 and December 31, 2022. Accrued interest receivable on both FHLB stock and Federal Reserve Bank stock is included in interest receivable on the consolidated balance sheets. </context>
|
us-gaap:InterestReceivable
|
The Corporation is required to maintain Federal Reserve Bank stock and FHLB stock as a member bank of both the Federal Reserve System and the FHLB, and in amounts as required by these institutions. These equity securities are “restricted” in that they can only be sold back to the respective institutions or another member institution at par. Therefore, they are less liquid than other marketable equity securities and their fair value is equal to amortized cost. The Corporation had FHLB stock of $ 143 million and $ 209 million at December 31, 2023 and 2022, respectively. The Corporation had Federal Reserve Bank stock of $ 87 million at both December 31, 2023 and 2022. Accrued interest receivable on FHLB stock totaled $ 4 million and $ 3 million at December 31, 2023 and 2022, respectively. There was no accrued interest receivable on Federal Reserve Bank stock at both December 31, 2023 and December 31, 2022. Accrued interest receivable on both FHLB stock and Federal Reserve Bank stock is included in interest receivable on the consolidated balance sheets.
|
text
|
3
|
monetaryItemType
|
text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation is required to maintain Federal Reserve Bank stock and FHLB stock as a member bank of both the Federal Reserve System and the FHLB, and in amounts as required by these institutions. These equity securities are “restricted” in that they can only be sold back to the respective institutions or another member institution at par. Therefore, they are less liquid than other marketable equity securities and their fair value is equal to amortized cost. The Corporation had FHLB stock of $ 143 million and $ 209 million at December 31, 2023 and 2022, respectively. The Corporation had Federal Reserve Bank stock of $ 87 million at both December 31, 2023 and 2022. Accrued interest receivable on FHLB stock totaled $ 4 million and $ 3 million at December 31, 2023 and 2022, respectively. There was no accrued interest receivable on Federal Reserve Bank stock at both December 31, 2023 and December 31, 2022. Accrued interest receivable on both FHLB stock and Federal Reserve Bank stock is included in interest receivable on the consolidated balance sheets. </context>
|
us-gaap:InterestReceivable
|
The Corporation's portfolio of equity securities with readily determinable fair values is primarily comprised of CRA Qualified Investment mutual funds and other mutual funds. At December 31, 2023 and 2022, the Corporation had equity securities with readily determinable fair values of $ 7 million and $ 6 million, respectively.
|
text
|
7
|
monetaryItemType
|
text: <entity> 7 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation's portfolio of equity securities with readily determinable fair values is primarily comprised of CRA Qualified Investment mutual funds and other mutual funds. At December 31, 2023 and 2022, the Corporation had equity securities with readily determinable fair values of $ 7 million and $ 6 million, respectively. </context>
|
us-gaap:EquitySecuritiesFvNi
|
The Corporation's portfolio of equity securities with readily determinable fair values is primarily comprised of CRA Qualified Investment mutual funds and other mutual funds. At December 31, 2023 and 2022, the Corporation had equity securities with readily determinable fair values of $ 7 million and $ 6 million, respectively.
|
text
|
6
|
monetaryItemType
|
text: <entity> 6 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation's portfolio of equity securities with readily determinable fair values is primarily comprised of CRA Qualified Investment mutual funds and other mutual funds. At December 31, 2023 and 2022, the Corporation had equity securities with readily determinable fair values of $ 7 million and $ 6 million, respectively. </context>
|
us-gaap:EquitySecuritiesFvNi
|
The Corporation's portfolio of equity securities without readily determinable fair values, which primarily consists of Visa Class B restricted shares and an investment in a private SBA loan fund, was carried at $ 35 million and $ 19 million at December 31, 2023 and 2022, respectively.
|
text
|
35
|
monetaryItemType
|
text: <entity> 35 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation's portfolio of equity securities without readily determinable fair values, which primarily consists of Visa Class B restricted shares and an investment in a private SBA loan fund, was carried at $ 35 million and $ 19 million at December 31, 2023 and 2022, respectively. </context>
|
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
|
The Corporation's portfolio of equity securities without readily determinable fair values, which primarily consists of Visa Class B restricted shares and an investment in a private SBA loan fund, was carried at $ 35 million and $ 19 million at December 31, 2023 and 2022, respectively.
|
text
|
19
|
monetaryItemType
|
text: <entity> 19 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation's portfolio of equity securities without readily determinable fair values, which primarily consists of Visa Class B restricted shares and an investment in a private SBA loan fund, was carried at $ 35 million and $ 19 million at December 31, 2023 and 2022, respectively. </context>
|
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
|
Accrued interest receivable on loans totaled $ 132 million at December 31, 2023, and $ 113 million at December 31, 2022, and is included in interest receivable on the consolidated balance sheets. Interest accrued but not received is reversed against interest income when a loan is placed on nonaccrual. The amount of accrued interest reversed totaled $ 2 million for the year ended December 31, 2023, approximately $ 491 ,000 for the year ended December 31, 2022, and approximately $ 574 ,000 for the year ended December 31, 2021.
|
text
|
132
|
monetaryItemType
|
text: <entity> 132 </entity> <entity type> monetaryItemType </entity type> <context> Accrued interest receivable on loans totaled $ 132 million at December 31, 2023, and $ 113 million at December 31, 2022, and is included in interest receivable on the consolidated balance sheets. Interest accrued but not received is reversed against interest income when a loan is placed on nonaccrual. The amount of accrued interest reversed totaled $ 2 million for the year ended December 31, 2023, approximately $ 491 ,000 for the year ended December 31, 2022, and approximately $ 574 ,000 for the year ended December 31, 2021. </context>
|
us-gaap:InterestReceivable
|
Accrued interest receivable on loans totaled $ 132 million at December 31, 2023, and $ 113 million at December 31, 2022, and is included in interest receivable on the consolidated balance sheets. Interest accrued but not received is reversed against interest income when a loan is placed on nonaccrual. The amount of accrued interest reversed totaled $ 2 million for the year ended December 31, 2023, approximately $ 491 ,000 for the year ended December 31, 2022, and approximately $ 574 ,000 for the year ended December 31, 2021.
|
text
|
113
|
monetaryItemType
|
text: <entity> 113 </entity> <entity type> monetaryItemType </entity type> <context> Accrued interest receivable on loans totaled $ 132 million at December 31, 2023, and $ 113 million at December 31, 2022, and is included in interest receivable on the consolidated balance sheets. Interest accrued but not received is reversed against interest income when a loan is placed on nonaccrual. The amount of accrued interest reversed totaled $ 2 million for the year ended December 31, 2023, approximately $ 491 ,000 for the year ended December 31, 2022, and approximately $ 574 ,000 for the year ended December 31, 2021. </context>
|
us-gaap:InterestReceivable
|
(b) No interest income was recognized on nonaccrual loans for the year ended December 31, 2023. In addition, there were $ 23 million of nonaccrual loans for which there was no related ACLL at December 31, 2023.
|
text
|
No
|
monetaryItemType
|
text: <entity> No </entity> <entity type> monetaryItemType </entity type> <context> (b) No interest income was recognized on nonaccrual loans for the year ended December 31, 2023. In addition, there were $ 23 million of nonaccrual loans for which there was no related ACLL at December 31, 2023. </context>
|
us-gaap:FinancingReceivableNonaccrualInterestIncome
|
(b) No interest income was recognized on nonaccrual loans for the year ended December 31, 2023. In addition, there were $ 23 million of nonaccrual loans for which there was no related ACLL at December 31, 2023.
|
text
|
23
|
monetaryItemType
|
text: <entity> 23 </entity> <entity type> monetaryItemType </entity type> <context> (b) No interest income was recognized on nonaccrual loans for the year ended December 31, 2023. In addition, there were $ 23 million of nonaccrual loans for which there was no related ACLL at December 31, 2023. </context>
|
us-gaap:FinancingReceivableNonaccrualNoAllowance
|
(b) No interest income was recognized on nonaccrual loans for the year ended December 31, 2022. In addition, there were $ 11 million of nonaccrual loans for which there was no related ACLL at December 31, 2022.
|
text
|
No
|
monetaryItemType
|
text: <entity> No </entity> <entity type> monetaryItemType </entity type> <context> (b) No interest income was recognized on nonaccrual loans for the year ended December 31, 2022. In addition, there were $ 11 million of nonaccrual loans for which there was no related ACLL at December 31, 2022. </context>
|
us-gaap:FinancingReceivableNonaccrualInterestIncome
|
(b) No interest income was recognized on nonaccrual loans for the year ended December 31, 2022. In addition, there were $ 11 million of nonaccrual loans for which there was no related ACLL at December 31, 2022.
|
text
|
11
|
monetaryItemType
|
text: <entity> 11 </entity> <entity type> monetaryItemType </entity type> <context> (b) No interest income was recognized on nonaccrual loans for the year ended December 31, 2022. In addition, there were $ 11 million of nonaccrual loans for which there was no related ACLL at December 31, 2022. </context>
|
us-gaap:FinancingReceivableNonaccrualNoAllowance
|
(a) During the fourth quarter of 2023, the Corporation transferred $ 969 million of residential mortgages into held for sale and subsequently sold them for $ 844 million. After sale, the servicing has been retained for a short period until full servicing can be transferred to the purchaser.
|
text
|
969
|
monetaryItemType
|
text: <entity> 969 </entity> <entity type> monetaryItemType </entity type> <context> (a) During the fourth quarter of 2023, the Corporation transferred $ 969 million of residential mortgages into held for sale and subsequently sold them for $ 844 million. After sale, the servicing has been retained for a short period until full servicing can be transferred to the purchaser. </context>
|
us-gaap:TransferOfPortfolioLoansAndLeasesToHeldForSale1
|
(a) During the fourth quarter of 2023, the Corporation transferred $ 969 million of residential mortgages into held for sale and subsequently sold them for $ 844 million. After sale, the servicing has been retained for a short period until full servicing can be transferred to the purchaser.
|
text
|
844
|
monetaryItemType
|
text: <entity> 844 </entity> <entity type> monetaryItemType </entity type> <context> (a) During the fourth quarter of 2023, the Corporation transferred $ 969 million of residential mortgages into held for sale and subsequently sold them for $ 844 million. After sale, the servicing has been retained for a short period until full servicing can be transferred to the purchaser. </context>
|
us-gaap:ProceedsFromSaleOfLoansHeldForSale
|
Depreciation and amortization of premises and equipment totaled $ 30 million for 2023, $ 31 million for 2022, and $ 33 million for 2021.
|
text
|
30
|
monetaryItemType
|
text: <entity> 30 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation and amortization of premises and equipment totaled $ 30 million for 2023, $ 31 million for 2022, and $ 33 million for 2021. </context>
|
us-gaap:Depreciation
|
Depreciation and amortization of premises and equipment totaled $ 30 million for 2023, $ 31 million for 2022, and $ 33 million for 2021.
|
text
|
31
|
monetaryItemType
|
text: <entity> 31 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation and amortization of premises and equipment totaled $ 30 million for 2023, $ 31 million for 2022, and $ 33 million for 2021. </context>
|
us-gaap:Depreciation
|
Depreciation and amortization of premises and equipment totaled $ 30 million for 2023, $ 31 million for 2022, and $ 33 million for 2021.
|
text
|
33
|
monetaryItemType
|
text: <entity> 33 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation and amortization of premises and equipment totaled $ 30 million for 2023, $ 31 million for 2022, and $ 33 million for 2021. </context>
|
us-gaap:Depreciation
|
In November 2014, the Corporation issued $ 250 million of 10 -year subordinated notes, due January 2025 , and callable October 2024 . The subordinated notes have a fixed coupon interest rate of 4.25 % and were issued at a discount.
|
text
|
4.25
|
percentItemType
|
text: <entity> 4.25 </entity> <entity type> percentItemType </entity type> <context> In November 2014, the Corporation issued $ 250 million of 10 -year subordinated notes, due January 2025 , and callable October 2024 . The subordinated notes have a fixed coupon interest rate of 4.25 % and were issued at a discount. </context>
|
us-gaap:SubordinatedBorrowingInterestRate
|
In February 2023, the Corporation issued $ 300 million of 10 -year subordinated notes, due March 1, 2033 and redeemable (i) on the reset date of March 1, 2028 and any interest payment date thereafter, (ii) at any time on or after the three month period prior to the maturity date, and (iii) upon the occurrence of a Regulatory Capital Treatment Event (as defined in the Global Note). The subordinated notes have a fixed coupon interest rate of 6.625 % until the reset date, after which the rate will be equal to the Five-Year U.S. Treasury Rate as of the reset date plus 2.812 % per annum. The notes were issued at a discount.
|
text
|
6.625
|
percentItemType
|
text: <entity> 6.625 </entity> <entity type> percentItemType </entity type> <context> In February 2023, the Corporation issued $ 300 million of 10 -year subordinated notes, due March 1, 2033 and redeemable (i) on the reset date of March 1, 2028 and any interest payment date thereafter, (ii) at any time on or after the three month period prior to the maturity date, and (iii) upon the occurrence of a Regulatory Capital Treatment Event (as defined in the Global Note). The subordinated notes have a fixed coupon interest rate of 6.625 % until the reset date, after which the rate will be equal to the Five-Year U.S. Treasury Rate as of the reset date plus 2.812 % per annum. The notes were issued at a discount. </context>
|
us-gaap:SubordinatedBorrowingInterestRate
|
Under agreements with the FHLB of Chicago, FHLB advances are secured by pledging qualifying collateral of the subsidiary bank (such as residential mortgage, residential mortgage loans held for sale, home equity, CRE and investment securities). At December 31, 2023, the Corporation had $ 10.5 billion of total collateral capacity, primarily supported by pledged consumer and CRE loans and investment securities. At December 31, 2023, the FHLB advances had maturity or call dates ranging from
|
text
|
10.5
|
monetaryItemType
|
text: <entity> 10.5 </entity> <entity type> monetaryItemType </entity type> <context> Under agreements with the FHLB of Chicago, FHLB advances are secured by pledging qualifying collateral of the subsidiary bank (such as residential mortgage, residential mortgage loans held for sale, home equity, CRE and investment securities). At December 31, 2023, the Corporation had $ 10.5 billion of total collateral capacity, primarily supported by pledged consumer and CRE loans and investment securities. At December 31, 2023, the FHLB advances had maturity or call dates ranging from </context>
|
us-gaap:FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresCollateralPledged1
|
In June 2015, the Corporation issued 2.6 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 6.125 % Non-Cumulative Perpetual Preferred Stock, Series C, liquidation preference $ 1,000 per share. On June 15, 2021, the Corporation redeemed all remaining Series C depositary shares for $ 65 million.
|
text
|
2.6
|
sharesItemType
|
text: <entity> 2.6 </entity> <entity type> sharesItemType </entity type> <context> In June 2015, the Corporation issued 2.6 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 6.125 % Non-Cumulative Perpetual Preferred Stock, Series C, liquidation preference $ 1,000 per share. On June 15, 2021, the Corporation redeemed all remaining Series C depositary shares for $ 65 million. </context>
|
us-gaap:PreferredStockSharesIssued
|
In June 2015, the Corporation issued 2.6 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 6.125 % Non-Cumulative Perpetual Preferred Stock, Series C, liquidation preference $ 1,000 per share. On June 15, 2021, the Corporation redeemed all remaining Series C depositary shares for $ 65 million.
|
text
|
6.125
|
percentItemType
|
text: <entity> 6.125 </entity> <entity type> percentItemType </entity type> <context> In June 2015, the Corporation issued 2.6 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 6.125 % Non-Cumulative Perpetual Preferred Stock, Series C, liquidation preference $ 1,000 per share. On June 15, 2021, the Corporation redeemed all remaining Series C depositary shares for $ 65 million. </context>
|
us-gaap:PreferredStockDividendRatePercentage
|
In June 2015, the Corporation issued 2.6 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 6.125 % Non-Cumulative Perpetual Preferred Stock, Series C, liquidation preference $ 1,000 per share. On June 15, 2021, the Corporation redeemed all remaining Series C depositary shares for $ 65 million.
|
text
|
65
|
monetaryItemType
|
text: <entity> 65 </entity> <entity type> monetaryItemType </entity type> <context> In June 2015, the Corporation issued 2.6 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 6.125 % Non-Cumulative Perpetual Preferred Stock, Series C, liquidation preference $ 1,000 per share. On June 15, 2021, the Corporation redeemed all remaining Series C depositary shares for $ 65 million. </context>
|
us-gaap:PreferredStockRedemptionAmount
|
In September 2016, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.375 % Non-Cumulative Perpetual Preferred Stock, Series D, liquidation preference $ 1,000 per share. On July 25, 2017, the Board of Directors authorized the repurchase of up to $ 15 million of depositary shares of the Corporation's Series D Preferred Stock. During 2018, the Corporation repurchased approximately 22,000 depositary shares for $ 1 million. On September 15, 2021, the Corporation redeemed all remaining Series D depositary shares for $ 99 million.
|
text
|
4.0
|
sharesItemType
|
text: <entity> 4.0 </entity> <entity type> sharesItemType </entity type> <context> In September 2016, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.375 % Non-Cumulative Perpetual Preferred Stock, Series D, liquidation preference $ 1,000 per share. On July 25, 2017, the Board of Directors authorized the repurchase of up to $ 15 million of depositary shares of the Corporation's Series D Preferred Stock. During 2018, the Corporation repurchased approximately 22,000 depositary shares for $ 1 million. On September 15, 2021, the Corporation redeemed all remaining Series D depositary shares for $ 99 million. </context>
|
us-gaap:PreferredStockSharesIssued
|
In September 2016, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.375 % Non-Cumulative Perpetual Preferred Stock, Series D, liquidation preference $ 1,000 per share. On July 25, 2017, the Board of Directors authorized the repurchase of up to $ 15 million of depositary shares of the Corporation's Series D Preferred Stock. During 2018, the Corporation repurchased approximately 22,000 depositary shares for $ 1 million. On September 15, 2021, the Corporation redeemed all remaining Series D depositary shares for $ 99 million.
|
text
|
5.375
|
percentItemType
|
text: <entity> 5.375 </entity> <entity type> percentItemType </entity type> <context> In September 2016, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.375 % Non-Cumulative Perpetual Preferred Stock, Series D, liquidation preference $ 1,000 per share. On July 25, 2017, the Board of Directors authorized the repurchase of up to $ 15 million of depositary shares of the Corporation's Series D Preferred Stock. During 2018, the Corporation repurchased approximately 22,000 depositary shares for $ 1 million. On September 15, 2021, the Corporation redeemed all remaining Series D depositary shares for $ 99 million. </context>
|
us-gaap:PreferredStockDividendRatePercentage
|
In September 2016, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.375 % Non-Cumulative Perpetual Preferred Stock, Series D, liquidation preference $ 1,000 per share. On July 25, 2017, the Board of Directors authorized the repurchase of up to $ 15 million of depositary shares of the Corporation's Series D Preferred Stock. During 2018, the Corporation repurchased approximately 22,000 depositary shares for $ 1 million. On September 15, 2021, the Corporation redeemed all remaining Series D depositary shares for $ 99 million.
|
text
|
15
|
monetaryItemType
|
text: <entity> 15 </entity> <entity type> monetaryItemType </entity type> <context> In September 2016, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.375 % Non-Cumulative Perpetual Preferred Stock, Series D, liquidation preference $ 1,000 per share. On July 25, 2017, the Board of Directors authorized the repurchase of up to $ 15 million of depositary shares of the Corporation's Series D Preferred Stock. During 2018, the Corporation repurchased approximately 22,000 depositary shares for $ 1 million. On September 15, 2021, the Corporation redeemed all remaining Series D depositary shares for $ 99 million. </context>
|
us-gaap:StockRepurchaseProgramAuthorizedAmount1
|
In September 2016, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.375 % Non-Cumulative Perpetual Preferred Stock, Series D, liquidation preference $ 1,000 per share. On July 25, 2017, the Board of Directors authorized the repurchase of up to $ 15 million of depositary shares of the Corporation's Series D Preferred Stock. During 2018, the Corporation repurchased approximately 22,000 depositary shares for $ 1 million. On September 15, 2021, the Corporation redeemed all remaining Series D depositary shares for $ 99 million.
|
text
|
22000
|
sharesItemType
|
text: <entity> 22000 </entity> <entity type> sharesItemType </entity type> <context> In September 2016, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.375 % Non-Cumulative Perpetual Preferred Stock, Series D, liquidation preference $ 1,000 per share. On July 25, 2017, the Board of Directors authorized the repurchase of up to $ 15 million of depositary shares of the Corporation's Series D Preferred Stock. During 2018, the Corporation repurchased approximately 22,000 depositary shares for $ 1 million. On September 15, 2021, the Corporation redeemed all remaining Series D depositary shares for $ 99 million. </context>
|
us-gaap:StockRepurchasedDuringPeriodShares
|
In September 2016, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.375 % Non-Cumulative Perpetual Preferred Stock, Series D, liquidation preference $ 1,000 per share. On July 25, 2017, the Board of Directors authorized the repurchase of up to $ 15 million of depositary shares of the Corporation's Series D Preferred Stock. During 2018, the Corporation repurchased approximately 22,000 depositary shares for $ 1 million. On September 15, 2021, the Corporation redeemed all remaining Series D depositary shares for $ 99 million.
|
text
|
1
|
monetaryItemType
|
text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> In September 2016, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.375 % Non-Cumulative Perpetual Preferred Stock, Series D, liquidation preference $ 1,000 per share. On July 25, 2017, the Board of Directors authorized the repurchase of up to $ 15 million of depositary shares of the Corporation's Series D Preferred Stock. During 2018, the Corporation repurchased approximately 22,000 depositary shares for $ 1 million. On September 15, 2021, the Corporation redeemed all remaining Series D depositary shares for $ 99 million. </context>
|
us-gaap:PreferredStockRedemptionAmount
|
In September 2016, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.375 % Non-Cumulative Perpetual Preferred Stock, Series D, liquidation preference $ 1,000 per share. On July 25, 2017, the Board of Directors authorized the repurchase of up to $ 15 million of depositary shares of the Corporation's Series D Preferred Stock. During 2018, the Corporation repurchased approximately 22,000 depositary shares for $ 1 million. On September 15, 2021, the Corporation redeemed all remaining Series D depositary shares for $ 99 million.
|
text
|
99
|
monetaryItemType
|
text: <entity> 99 </entity> <entity type> monetaryItemType </entity type> <context> In September 2016, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.375 % Non-Cumulative Perpetual Preferred Stock, Series D, liquidation preference $ 1,000 per share. On July 25, 2017, the Board of Directors authorized the repurchase of up to $ 15 million of depositary shares of the Corporation's Series D Preferred Stock. During 2018, the Corporation repurchased approximately 22,000 depositary shares for $ 1 million. On September 15, 2021, the Corporation redeemed all remaining Series D depositary shares for $ 99 million. </context>
|
us-gaap:PreferredStockRedemptionAmount
|
In September 2018, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.875 % Non-Cumulative Perpetual Preferred Stock, Series E, liquidation preference $ 1,000 per share. Dividends on the Series E Preferred Stock are payable quarterly in arrears only when, as and if declared by the Board of Directors at a rate per annum equal to 5.875%. Shares of the Series E Preferred Stock have priority over the Corporation’s common stock with regard to the payment of dividends and distributions upon liquidation, dissolution or winding up. As such, the Corporation may not pay dividends on or repurchase, redeem, or otherwise acquire for consideration shares of its common stock unless dividends for the Series E Preferred Stock have been declared for that period, and sufficient funds have been set aside to make payment. The Series E Preferred Stock may be redeemed by the Corporation at its option (i) either in whole or in part, from time to time, on any dividend payment date on or after the dividend payment date occurring on December 15, 2023, or (ii) in whole but not in part, at any time within 90 days following certain regulatory capital treatment events, in each case at a redemption price of $1,000 per share (equivalent to $25 per depositary share), plus any applicable dividends. Except in certain limited circumstances, the Series E Preferred Stock does not have any voting rights.
|
text
|
4.0
|
sharesItemType
|
text: <entity> 4.0 </entity> <entity type> sharesItemType </entity type> <context> In September 2018, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.875 % Non-Cumulative Perpetual Preferred Stock, Series E, liquidation preference $ 1,000 per share. Dividends on the Series E Preferred Stock are payable quarterly in arrears only when, as and if declared by the Board of Directors at a rate per annum equal to 5.875%. Shares of the Series E Preferred Stock have priority over the Corporation’s common stock with regard to the payment of dividends and distributions upon liquidation, dissolution or winding up. As such, the Corporation may not pay dividends on or repurchase, redeem, or otherwise acquire for consideration shares of its common stock unless dividends for the Series E Preferred Stock have been declared for that period, and sufficient funds have been set aside to make payment. The Series E Preferred Stock may be redeemed by the Corporation at its option (i) either in whole or in part, from time to time, on any dividend payment date on or after the dividend payment date occurring on December 15, 2023, or (ii) in whole but not in part, at any time within 90 days following certain regulatory capital treatment events, in each case at a redemption price of $1,000 per share (equivalent to $25 per depositary share), plus any applicable dividends. Except in certain limited circumstances, the Series E Preferred Stock does not have any voting rights. </context>
|
us-gaap:PreferredStockSharesIssued
|
In September 2018, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.875 % Non-Cumulative Perpetual Preferred Stock, Series E, liquidation preference $ 1,000 per share. Dividends on the Series E Preferred Stock are payable quarterly in arrears only when, as and if declared by the Board of Directors at a rate per annum equal to 5.875%. Shares of the Series E Preferred Stock have priority over the Corporation’s common stock with regard to the payment of dividends and distributions upon liquidation, dissolution or winding up. As such, the Corporation may not pay dividends on or repurchase, redeem, or otherwise acquire for consideration shares of its common stock unless dividends for the Series E Preferred Stock have been declared for that period, and sufficient funds have been set aside to make payment. The Series E Preferred Stock may be redeemed by the Corporation at its option (i) either in whole or in part, from time to time, on any dividend payment date on or after the dividend payment date occurring on December 15, 2023, or (ii) in whole but not in part, at any time within 90 days following certain regulatory capital treatment events, in each case at a redemption price of $1,000 per share (equivalent to $25 per depositary share), plus any applicable dividends. Except in certain limited circumstances, the Series E Preferred Stock does not have any voting rights.
|
text
|
5.875
|
percentItemType
|
text: <entity> 5.875 </entity> <entity type> percentItemType </entity type> <context> In September 2018, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.875 % Non-Cumulative Perpetual Preferred Stock, Series E, liquidation preference $ 1,000 per share. Dividends on the Series E Preferred Stock are payable quarterly in arrears only when, as and if declared by the Board of Directors at a rate per annum equal to 5.875%. Shares of the Series E Preferred Stock have priority over the Corporation’s common stock with regard to the payment of dividends and distributions upon liquidation, dissolution or winding up. As such, the Corporation may not pay dividends on or repurchase, redeem, or otherwise acquire for consideration shares of its common stock unless dividends for the Series E Preferred Stock have been declared for that period, and sufficient funds have been set aside to make payment. The Series E Preferred Stock may be redeemed by the Corporation at its option (i) either in whole or in part, from time to time, on any dividend payment date on or after the dividend payment date occurring on December 15, 2023, or (ii) in whole but not in part, at any time within 90 days following certain regulatory capital treatment events, in each case at a redemption price of $1,000 per share (equivalent to $25 per depositary share), plus any applicable dividends. Except in certain limited circumstances, the Series E Preferred Stock does not have any voting rights. </context>
|
us-gaap:PreferredStockDividendRatePercentage
|
In June 2020, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.625 % Non-Cumulative Perpetual Preferred Stock, Series F, liquidation preference $ 1,000 per share. Dividends on the Series F Preferred Stock are payable quarterly in arrears only when, as and if declared by the Board of Directors at a rate per annum equal to 5.625%. Shares of the Series F Preferred Stock have priority over the Corporation’s common stock with regard to the payment of dividends and distributions upon liquidation, dissolution or winding up. As such, the Corporation may not pay dividends on or repurchase, redeem, or otherwise acquire for consideration shares of its common stock unless dividends for the Series F Preferred Stock have been declared for that period, and sufficient funds have been set aside to make payment. The Series F Preferred Stock may be redeemed by the Corporation at its option (i) either in whole or in part, from time to time, on any dividend payment date on or after the dividend payment date occurring on September 15, 2025, or (ii) in whole but not
|
text
|
4.0
|
sharesItemType
|
text: <entity> 4.0 </entity> <entity type> sharesItemType </entity type> <context> In June 2020, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.625 % Non-Cumulative Perpetual Preferred Stock, Series F, liquidation preference $ 1,000 per share. Dividends on the Series F Preferred Stock are payable quarterly in arrears only when, as and if declared by the Board of Directors at a rate per annum equal to 5.625%. Shares of the Series F Preferred Stock have priority over the Corporation’s common stock with regard to the payment of dividends and distributions upon liquidation, dissolution or winding up. As such, the Corporation may not pay dividends on or repurchase, redeem, or otherwise acquire for consideration shares of its common stock unless dividends for the Series F Preferred Stock have been declared for that period, and sufficient funds have been set aside to make payment. The Series F Preferred Stock may be redeemed by the Corporation at its option (i) either in whole or in part, from time to time, on any dividend payment date on or after the dividend payment date occurring on September 15, 2025, or (ii) in whole but not </context>
|
us-gaap:PreferredStockSharesIssued
|
In June 2020, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.625 % Non-Cumulative Perpetual Preferred Stock, Series F, liquidation preference $ 1,000 per share. Dividends on the Series F Preferred Stock are payable quarterly in arrears only when, as and if declared by the Board of Directors at a rate per annum equal to 5.625%. Shares of the Series F Preferred Stock have priority over the Corporation’s common stock with regard to the payment of dividends and distributions upon liquidation, dissolution or winding up. As such, the Corporation may not pay dividends on or repurchase, redeem, or otherwise acquire for consideration shares of its common stock unless dividends for the Series F Preferred Stock have been declared for that period, and sufficient funds have been set aside to make payment. The Series F Preferred Stock may be redeemed by the Corporation at its option (i) either in whole or in part, from time to time, on any dividend payment date on or after the dividend payment date occurring on September 15, 2025, or (ii) in whole but not
|
text
|
5.625
|
percentItemType
|
text: <entity> 5.625 </entity> <entity type> percentItemType </entity type> <context> In June 2020, the Corporation issued 4.0 million depositary shares, each representing a 1/40th interest in a share of the Corporation’s 5.625 % Non-Cumulative Perpetual Preferred Stock, Series F, liquidation preference $ 1,000 per share. Dividends on the Series F Preferred Stock are payable quarterly in arrears only when, as and if declared by the Board of Directors at a rate per annum equal to 5.625%. Shares of the Series F Preferred Stock have priority over the Corporation’s common stock with regard to the payment of dividends and distributions upon liquidation, dissolution or winding up. As such, the Corporation may not pay dividends on or repurchase, redeem, or otherwise acquire for consideration shares of its common stock unless dividends for the Series F Preferred Stock have been declared for that period, and sufficient funds have been set aside to make payment. The Series F Preferred Stock may be redeemed by the Corporation at its option (i) either in whole or in part, from time to time, on any dividend payment date on or after the dividend payment date occurring on September 15, 2025, or (ii) in whole but not </context>
|
us-gaap:PreferredStockDividendRatePercentage
|
In 2023, the Board of Directors did not approve any additional authorizations for the repurchase of the Corporation's common stock. In 2021, the Board of Directors approved additional authorizations for the repurchase of up to $ 100 million of the Corporation’s common stock. During both 2023 and 2022, the Corporation did not repurchase any shares under the share repurchase program.
|
text
|
not
|
monetaryItemType
|
text: <entity> not </entity> <entity type> monetaryItemType </entity type> <context> In 2023, the Board of Directors did not approve any additional authorizations for the repurchase of the Corporation's common stock. In 2021, the Board of Directors approved additional authorizations for the repurchase of up to $ 100 million of the Corporation’s common stock. During both 2023 and 2022, the Corporation did not repurchase any shares under the share repurchase program. </context>
|
us-gaap:StockRepurchaseProgramAuthorizedAmount1
|
In 2023, the Board of Directors did not approve any additional authorizations for the repurchase of the Corporation's common stock. In 2021, the Board of Directors approved additional authorizations for the repurchase of up to $ 100 million of the Corporation’s common stock. During both 2023 and 2022, the Corporation did not repurchase any shares under the share repurchase program.
|
text
|
100
|
monetaryItemType
|
text: <entity> 100 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, the Board of Directors did not approve any additional authorizations for the repurchase of the Corporation's common stock. In 2021, the Board of Directors approved additional authorizations for the repurchase of up to $ 100 million of the Corporation’s common stock. During both 2023 and 2022, the Corporation did not repurchase any shares under the share repurchase program. </context>
|
us-gaap:StockRepurchaseProgramAuthorizedAmount1
|
In 2023, the Board of Directors did not approve any additional authorizations for the repurchase of the Corporation's common stock. In 2021, the Board of Directors approved additional authorizations for the repurchase of up to $ 100 million of the Corporation’s common stock. During both 2023 and 2022, the Corporation did not repurchase any shares under the share repurchase program.
|
text
|
not
|
sharesItemType
|
text: <entity> not </entity> <entity type> sharesItemType </entity type> <context> In 2023, the Board of Directors did not approve any additional authorizations for the repurchase of the Corporation's common stock. In 2021, the Board of Directors approved additional authorizations for the repurchase of up to $ 100 million of the Corporation’s common stock. During both 2023 and 2022, the Corporation did not repurchase any shares under the share repurchase program. </context>
|
us-gaap:StockRepurchasedDuringPeriodShares
|
As of December 31, 2023, $ 80 million remained available to repurchase shares of common stock under previously approved Board of Director authorizations. Any repurchase of shares under this authorization will be based on market and investment opportunities, capital levels, growth prospects, and any necessary regulatory approvals and other regulatory constraints. Such repurchases may occur from time to time in open market purchases, block transactions, private transactions, accelerated share repurchase programs, or similar facilities.
|
text
|
80
|
monetaryItemType
|
text: <entity> 80 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, $ 80 million remained available to repurchase shares of common stock under previously approved Board of Director authorizations. Any repurchase of shares under this authorization will be based on market and investment opportunities, capital levels, growth prospects, and any necessary regulatory approvals and other regulatory constraints. Such repurchases may occur from time to time in open market purchases, block transactions, private transactions, accelerated share repurchase programs, or similar facilities. </context>
|
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
|
The Corporation also repurchased shares in satisfaction of minimum tax withholding obligations in connection with settlements of equity compensation totaling $ 7 million ( 297,564 shares at an average cost per common share of $ 22.16 ) during 2023, compared to $ 6 million ( 267,605 shares at an average cost per common share of $ 24.22 ) during 2022.
|
text
|
7
|
monetaryItemType
|
text: <entity> 7 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation also repurchased shares in satisfaction of minimum tax withholding obligations in connection with settlements of equity compensation totaling $ 7 million ( 297,564 shares at an average cost per common share of $ 22.16 ) during 2023, compared to $ 6 million ( 267,605 shares at an average cost per common share of $ 24.22 ) during 2022. </context>
|
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
The Corporation also repurchased shares in satisfaction of minimum tax withholding obligations in connection with settlements of equity compensation totaling $ 7 million ( 297,564 shares at an average cost per common share of $ 22.16 ) during 2023, compared to $ 6 million ( 267,605 shares at an average cost per common share of $ 24.22 ) during 2022.
|
text
|
297564
|
sharesItemType
|
text: <entity> 297564 </entity> <entity type> sharesItemType </entity type> <context> The Corporation also repurchased shares in satisfaction of minimum tax withholding obligations in connection with settlements of equity compensation totaling $ 7 million ( 297,564 shares at an average cost per common share of $ 22.16 ) during 2023, compared to $ 6 million ( 267,605 shares at an average cost per common share of $ 24.22 ) during 2022. </context>
|
us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
|
The Corporation also repurchased shares in satisfaction of minimum tax withholding obligations in connection with settlements of equity compensation totaling $ 7 million ( 297,564 shares at an average cost per common share of $ 22.16 ) during 2023, compared to $ 6 million ( 267,605 shares at an average cost per common share of $ 24.22 ) during 2022.
|
text
|
6
|
monetaryItemType
|
text: <entity> 6 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation also repurchased shares in satisfaction of minimum tax withholding obligations in connection with settlements of equity compensation totaling $ 7 million ( 297,564 shares at an average cost per common share of $ 22.16 ) during 2023, compared to $ 6 million ( 267,605 shares at an average cost per common share of $ 24.22 ) during 2022. </context>
|
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
The Corporation also repurchased shares in satisfaction of minimum tax withholding obligations in connection with settlements of equity compensation totaling $ 7 million ( 297,564 shares at an average cost per common share of $ 22.16 ) during 2023, compared to $ 6 million ( 267,605 shares at an average cost per common share of $ 24.22 ) during 2022.
|
text
|
267605
|
sharesItemType
|
text: <entity> 267605 </entity> <entity type> sharesItemType </entity type> <context> The Corporation also repurchased shares in satisfaction of minimum tax withholding obligations in connection with settlements of equity compensation totaling $ 7 million ( 297,564 shares at an average cost per common share of $ 22.16 ) during 2023, compared to $ 6 million ( 267,605 shares at an average cost per common share of $ 24.22 ) during 2022. </context>
|
us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
|
Intrinsic value represents the amount by which the fair market value of the underlying stock exceeds the exercise price of the stock option. For the years ended December 31, 2023, 2022, and 2021, the intrinsic value of stock options exercised was approximately $ 518 ,000, $ 4 million, and $ 9 million, respectively. The total fair value of stock options that vested was approximately $ 943 ,000 for the year ended December 31, 2023, $ 2 million for the year ended December 31, 2022, and $ 4 million for the year ended December 31, 2021.
|
text
|
518
|
monetaryItemType
|
text: <entity> 518 </entity> <entity type> monetaryItemType </entity type> <context> Intrinsic value represents the amount by which the fair market value of the underlying stock exceeds the exercise price of the stock option. For the years ended December 31, 2023, 2022, and 2021, the intrinsic value of stock options exercised was approximately $ 518 ,000, $ 4 million, and $ 9 million, respectively. The total fair value of stock options that vested was approximately $ 943 ,000 for the year ended December 31, 2023, $ 2 million for the year ended December 31, 2022, and $ 4 million for the year ended December 31, 2021. </context>
|
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
Intrinsic value represents the amount by which the fair market value of the underlying stock exceeds the exercise price of the stock option. For the years ended December 31, 2023, 2022, and 2021, the intrinsic value of stock options exercised was approximately $ 518 ,000, $ 4 million, and $ 9 million, respectively. The total fair value of stock options that vested was approximately $ 943 ,000 for the year ended December 31, 2023, $ 2 million for the year ended December 31, 2022, and $ 4 million for the year ended December 31, 2021.
|
text
|
4
|
monetaryItemType
|
text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> Intrinsic value represents the amount by which the fair market value of the underlying stock exceeds the exercise price of the stock option. For the years ended December 31, 2023, 2022, and 2021, the intrinsic value of stock options exercised was approximately $ 518 ,000, $ 4 million, and $ 9 million, respectively. The total fair value of stock options that vested was approximately $ 943 ,000 for the year ended December 31, 2023, $ 2 million for the year ended December 31, 2022, and $ 4 million for the year ended December 31, 2021. </context>
|
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
Intrinsic value represents the amount by which the fair market value of the underlying stock exceeds the exercise price of the stock option. For the years ended December 31, 2023, 2022, and 2021, the intrinsic value of stock options exercised was approximately $ 518 ,000, $ 4 million, and $ 9 million, respectively. The total fair value of stock options that vested was approximately $ 943 ,000 for the year ended December 31, 2023, $ 2 million for the year ended December 31, 2022, and $ 4 million for the year ended December 31, 2021.
|
text
|
9
|
monetaryItemType
|
text: <entity> 9 </entity> <entity type> monetaryItemType </entity type> <context> Intrinsic value represents the amount by which the fair market value of the underlying stock exceeds the exercise price of the stock option. For the years ended December 31, 2023, 2022, and 2021, the intrinsic value of stock options exercised was approximately $ 518 ,000, $ 4 million, and $ 9 million, respectively. The total fair value of stock options that vested was approximately $ 943 ,000 for the year ended December 31, 2023, $ 2 million for the year ended December 31, 2022, and $ 4 million for the year ended December 31, 2021. </context>
|
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
Intrinsic value represents the amount by which the fair market value of the underlying stock exceeds the exercise price of the stock option. For the years ended December 31, 2023, 2022, and 2021, the intrinsic value of stock options exercised was approximately $ 518 ,000, $ 4 million, and $ 9 million, respectively. The total fair value of stock options that vested was approximately $ 943 ,000 for the year ended December 31, 2023, $ 2 million for the year ended December 31, 2022, and $ 4 million for the year ended December 31, 2021.
|
text
|
943
|
monetaryItemType
|
text: <entity> 943 </entity> <entity type> monetaryItemType </entity type> <context> Intrinsic value represents the amount by which the fair market value of the underlying stock exceeds the exercise price of the stock option. For the years ended December 31, 2023, 2022, and 2021, the intrinsic value of stock options exercised was approximately $ 518 ,000, $ 4 million, and $ 9 million, respectively. The total fair value of stock options that vested was approximately $ 943 ,000 for the year ended December 31, 2023, $ 2 million for the year ended December 31, 2022, and $ 4 million for the year ended December 31, 2021. </context>
|
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
Intrinsic value represents the amount by which the fair market value of the underlying stock exceeds the exercise price of the stock option. For the years ended December 31, 2023, 2022, and 2021, the intrinsic value of stock options exercised was approximately $ 518 ,000, $ 4 million, and $ 9 million, respectively. The total fair value of stock options that vested was approximately $ 943 ,000 for the year ended December 31, 2023, $ 2 million for the year ended December 31, 2022, and $ 4 million for the year ended December 31, 2021.
|
text
|
2
|
monetaryItemType
|
text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> Intrinsic value represents the amount by which the fair market value of the underlying stock exceeds the exercise price of the stock option. For the years ended December 31, 2023, 2022, and 2021, the intrinsic value of stock options exercised was approximately $ 518 ,000, $ 4 million, and $ 9 million, respectively. The total fair value of stock options that vested was approximately $ 943 ,000 for the year ended December 31, 2023, $ 2 million for the year ended December 31, 2022, and $ 4 million for the year ended December 31, 2021. </context>
|
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
Intrinsic value represents the amount by which the fair market value of the underlying stock exceeds the exercise price of the stock option. For the years ended December 31, 2023, 2022, and 2021, the intrinsic value of stock options exercised was approximately $ 518 ,000, $ 4 million, and $ 9 million, respectively. The total fair value of stock options that vested was approximately $ 943 ,000 for the year ended December 31, 2023, $ 2 million for the year ended December 31, 2022, and $ 4 million for the year ended December 31, 2021.
|
text
|
4
|
monetaryItemType
|
text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> Intrinsic value represents the amount by which the fair market value of the underlying stock exceeds the exercise price of the stock option. For the years ended December 31, 2023, 2022, and 2021, the intrinsic value of stock options exercised was approximately $ 518 ,000, $ 4 million, and $ 9 million, respectively. The total fair value of stock options that vested was approximately $ 943 ,000 for the year ended December 31, 2023, $ 2 million for the year ended December 31, 2022, and $ 4 million for the year ended December 31, 2021. </context>
|
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
For the years ended December 31, 2023, 2022, and 2021, the Corporation recognized compensation expense of approximately $ 333 ,000, approximately $ 710 ,000, and $ 1 million, respectively, for the vesting of stock options. Compensation expense for 2023 related to the accelerated vesting of stock options granted to retirement eligible colleagues was immaterial . At December 31, 2023, the Corporation had approximately $ 32 ,000 of unrecognized compensation expense related to stock options that is expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2024 .
|
text
|
333
|
monetaryItemType
|
text: <entity> 333 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2023, 2022, and 2021, the Corporation recognized compensation expense of approximately $ 333 ,000, approximately $ 710 ,000, and $ 1 million, respectively, for the vesting of stock options. Compensation expense for 2023 related to the accelerated vesting of stock options granted to retirement eligible colleagues was immaterial . At December 31, 2023, the Corporation had approximately $ 32 ,000 of unrecognized compensation expense related to stock options that is expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2024 . </context>
|
us-gaap:AllocatedShareBasedCompensationExpense
|
For the years ended December 31, 2023, 2022, and 2021, the Corporation recognized compensation expense of approximately $ 333 ,000, approximately $ 710 ,000, and $ 1 million, respectively, for the vesting of stock options. Compensation expense for 2023 related to the accelerated vesting of stock options granted to retirement eligible colleagues was immaterial . At December 31, 2023, the Corporation had approximately $ 32 ,000 of unrecognized compensation expense related to stock options that is expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2024 .
|
text
|
710
|
monetaryItemType
|
text: <entity> 710 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2023, 2022, and 2021, the Corporation recognized compensation expense of approximately $ 333 ,000, approximately $ 710 ,000, and $ 1 million, respectively, for the vesting of stock options. Compensation expense for 2023 related to the accelerated vesting of stock options granted to retirement eligible colleagues was immaterial . At December 31, 2023, the Corporation had approximately $ 32 ,000 of unrecognized compensation expense related to stock options that is expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2024 . </context>
|
us-gaap:AllocatedShareBasedCompensationExpense
|
For the years ended December 31, 2023, 2022, and 2021, the Corporation recognized compensation expense of approximately $ 333 ,000, approximately $ 710 ,000, and $ 1 million, respectively, for the vesting of stock options. Compensation expense for 2023 related to the accelerated vesting of stock options granted to retirement eligible colleagues was immaterial . At December 31, 2023, the Corporation had approximately $ 32 ,000 of unrecognized compensation expense related to stock options that is expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2024 .
|
text
|
1
|
monetaryItemType
|
text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2023, 2022, and 2021, the Corporation recognized compensation expense of approximately $ 333 ,000, approximately $ 710 ,000, and $ 1 million, respectively, for the vesting of stock options. Compensation expense for 2023 related to the accelerated vesting of stock options granted to retirement eligible colleagues was immaterial . At December 31, 2023, the Corporation had approximately $ 32 ,000 of unrecognized compensation expense related to stock options that is expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2024 . </context>
|
us-gaap:AllocatedShareBasedCompensationExpense
|
For the years ended December 31, 2023, 2022, and 2021, the Corporation recognized compensation expense of approximately $ 333 ,000, approximately $ 710 ,000, and $ 1 million, respectively, for the vesting of stock options. Compensation expense for 2023 related to the accelerated vesting of stock options granted to retirement eligible colleagues was immaterial . At December 31, 2023, the Corporation had approximately $ 32 ,000 of unrecognized compensation expense related to stock options that is expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2024 .
|
text
|
immaterial
|
monetaryItemType
|
text: <entity> immaterial </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2023, 2022, and 2021, the Corporation recognized compensation expense of approximately $ 333 ,000, approximately $ 710 ,000, and $ 1 million, respectively, for the vesting of stock options. Compensation expense for 2023 related to the accelerated vesting of stock options granted to retirement eligible colleagues was immaterial . At December 31, 2023, the Corporation had approximately $ 32 ,000 of unrecognized compensation expense related to stock options that is expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2024 . </context>
|
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
|
For the years ended December 31, 2023, 2022, and 2021, the Corporation recognized compensation expense of approximately $ 333 ,000, approximately $ 710 ,000, and $ 1 million, respectively, for the vesting of stock options. Compensation expense for 2023 related to the accelerated vesting of stock options granted to retirement eligible colleagues was immaterial . At December 31, 2023, the Corporation had approximately $ 32 ,000 of unrecognized compensation expense related to stock options that is expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2024 .
|
text
|
32
|
monetaryItemType
|
text: <entity> 32 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2023, 2022, and 2021, the Corporation recognized compensation expense of approximately $ 333 ,000, approximately $ 710 ,000, and $ 1 million, respectively, for the vesting of stock options. Compensation expense for 2023 related to the accelerated vesting of stock options granted to retirement eligible colleagues was immaterial . At December 31, 2023, the Corporation had approximately $ 32 ,000 of unrecognized compensation expense related to stock options that is expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2024 . </context>
|
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
The Corporation amortizes the expense related to restricted stock awards as compensation expense over the vesting period specified in the grant's award agreement. Expense for restricted stock awards of $ 17 million was recorded for the year ended December 31, 2023, $ 16 million for the year ended December 31, 2022 and $ 15 million for the year ended December 31, 2021. Included in compensation expense for 2023 was $ 3 million of expense for the accelerated vesting of restricted stock awards granted to retirement eligible colleagues. The Corporation had $ 20 million of unrecognized compensation costs related to restricted stock awards at December 31, 2023 that are expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2027 .
|
text
|
17
|
monetaryItemType
|
text: <entity> 17 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation amortizes the expense related to restricted stock awards as compensation expense over the vesting period specified in the grant's award agreement. Expense for restricted stock awards of $ 17 million was recorded for the year ended December 31, 2023, $ 16 million for the year ended December 31, 2022 and $ 15 million for the year ended December 31, 2021. Included in compensation expense for 2023 was $ 3 million of expense for the accelerated vesting of restricted stock awards granted to retirement eligible colleagues. The Corporation had $ 20 million of unrecognized compensation costs related to restricted stock awards at December 31, 2023 that are expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2027 . </context>
|
us-gaap:AllocatedShareBasedCompensationExpense
|
The Corporation amortizes the expense related to restricted stock awards as compensation expense over the vesting period specified in the grant's award agreement. Expense for restricted stock awards of $ 17 million was recorded for the year ended December 31, 2023, $ 16 million for the year ended December 31, 2022 and $ 15 million for the year ended December 31, 2021. Included in compensation expense for 2023 was $ 3 million of expense for the accelerated vesting of restricted stock awards granted to retirement eligible colleagues. The Corporation had $ 20 million of unrecognized compensation costs related to restricted stock awards at December 31, 2023 that are expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2027 .
|
text
|
16
|
monetaryItemType
|
text: <entity> 16 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation amortizes the expense related to restricted stock awards as compensation expense over the vesting period specified in the grant's award agreement. Expense for restricted stock awards of $ 17 million was recorded for the year ended December 31, 2023, $ 16 million for the year ended December 31, 2022 and $ 15 million for the year ended December 31, 2021. Included in compensation expense for 2023 was $ 3 million of expense for the accelerated vesting of restricted stock awards granted to retirement eligible colleagues. The Corporation had $ 20 million of unrecognized compensation costs related to restricted stock awards at December 31, 2023 that are expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2027 . </context>
|
us-gaap:AllocatedShareBasedCompensationExpense
|
The Corporation amortizes the expense related to restricted stock awards as compensation expense over the vesting period specified in the grant's award agreement. Expense for restricted stock awards of $ 17 million was recorded for the year ended December 31, 2023, $ 16 million for the year ended December 31, 2022 and $ 15 million for the year ended December 31, 2021. Included in compensation expense for 2023 was $ 3 million of expense for the accelerated vesting of restricted stock awards granted to retirement eligible colleagues. The Corporation had $ 20 million of unrecognized compensation costs related to restricted stock awards at December 31, 2023 that are expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2027 .
|
text
|
15
|
monetaryItemType
|
text: <entity> 15 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation amortizes the expense related to restricted stock awards as compensation expense over the vesting period specified in the grant's award agreement. Expense for restricted stock awards of $ 17 million was recorded for the year ended December 31, 2023, $ 16 million for the year ended December 31, 2022 and $ 15 million for the year ended December 31, 2021. Included in compensation expense for 2023 was $ 3 million of expense for the accelerated vesting of restricted stock awards granted to retirement eligible colleagues. The Corporation had $ 20 million of unrecognized compensation costs related to restricted stock awards at December 31, 2023 that are expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2027 . </context>
|
us-gaap:AllocatedShareBasedCompensationExpense
|
The Corporation amortizes the expense related to restricted stock awards as compensation expense over the vesting period specified in the grant's award agreement. Expense for restricted stock awards of $ 17 million was recorded for the year ended December 31, 2023, $ 16 million for the year ended December 31, 2022 and $ 15 million for the year ended December 31, 2021. Included in compensation expense for 2023 was $ 3 million of expense for the accelerated vesting of restricted stock awards granted to retirement eligible colleagues. The Corporation had $ 20 million of unrecognized compensation costs related to restricted stock awards at December 31, 2023 that are expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2027 .
|
text
|
3
|
monetaryItemType
|
text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation amortizes the expense related to restricted stock awards as compensation expense over the vesting period specified in the grant's award agreement. Expense for restricted stock awards of $ 17 million was recorded for the year ended December 31, 2023, $ 16 million for the year ended December 31, 2022 and $ 15 million for the year ended December 31, 2021. Included in compensation expense for 2023 was $ 3 million of expense for the accelerated vesting of restricted stock awards granted to retirement eligible colleagues. The Corporation had $ 20 million of unrecognized compensation costs related to restricted stock awards at December 31, 2023 that are expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2027 . </context>
|
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
|
The Corporation amortizes the expense related to restricted stock awards as compensation expense over the vesting period specified in the grant's award agreement. Expense for restricted stock awards of $ 17 million was recorded for the year ended December 31, 2023, $ 16 million for the year ended December 31, 2022 and $ 15 million for the year ended December 31, 2021. Included in compensation expense for 2023 was $ 3 million of expense for the accelerated vesting of restricted stock awards granted to retirement eligible colleagues. The Corporation had $ 20 million of unrecognized compensation costs related to restricted stock awards at December 31, 2023 that are expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2027 .
|
text
|
20
|
monetaryItemType
|
text: <entity> 20 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation amortizes the expense related to restricted stock awards as compensation expense over the vesting period specified in the grant's award agreement. Expense for restricted stock awards of $ 17 million was recorded for the year ended December 31, 2023, $ 16 million for the year ended December 31, 2022 and $ 15 million for the year ended December 31, 2021. Included in compensation expense for 2023 was $ 3 million of expense for the accelerated vesting of restricted stock awards granted to retirement eligible colleagues. The Corporation had $ 20 million of unrecognized compensation costs related to restricted stock awards at December 31, 2023 that are expected to be recognized over the remaining requisite service periods that extend predominantly through the first quarter of 2027 . </context>
|
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
The RAP’s investments are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risks associated with certain investments and the level of uncertainty related to changes in the value of the investments, it is at least reasonably possible that changes in risks in the near term could materially affect the amounts reported. The investment objective for the RAP is to ensure there are sufficient assets to pay pension obligations when they come due while mitigating risks and providing prudent governance. The RAP has a diversified portfolio designed to provide liquidity, current income, and growth of income and principal, with anticipated asset allocation ranges of: equity securities 50 to 70 %, fixed-income securities 30 to 50 %, alternative securities 0 to 15 %, and other cash equivalents 0 to 10 %. Based on changes in economic and market conditions, the Corporation could be outside of the allocation ranges for brief periods of time. The asset allocation for the RAP as of the December 31, 2023 and 2022 measurement dates, respectively, by asset category were as follows:
|
text
|
50
|
percentItemType
|
text: <entity> 50 </entity> <entity type> percentItemType </entity type> <context> The RAP’s investments are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risks associated with certain investments and the level of uncertainty related to changes in the value of the investments, it is at least reasonably possible that changes in risks in the near term could materially affect the amounts reported. The investment objective for the RAP is to ensure there are sufficient assets to pay pension obligations when they come due while mitigating risks and providing prudent governance. The RAP has a diversified portfolio designed to provide liquidity, current income, and growth of income and principal, with anticipated asset allocation ranges of: equity securities 50 to 70 %, fixed-income securities 30 to 50 %, alternative securities 0 to 15 %, and other cash equivalents 0 to 10 %. Based on changes in economic and market conditions, the Corporation could be outside of the allocation ranges for brief periods of time. The asset allocation for the RAP as of the December 31, 2023 and 2022 measurement dates, respectively, by asset category were as follows: </context>
|
us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
|
The RAP’s investments are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risks associated with certain investments and the level of uncertainty related to changes in the value of the investments, it is at least reasonably possible that changes in risks in the near term could materially affect the amounts reported. The investment objective for the RAP is to ensure there are sufficient assets to pay pension obligations when they come due while mitigating risks and providing prudent governance. The RAP has a diversified portfolio designed to provide liquidity, current income, and growth of income and principal, with anticipated asset allocation ranges of: equity securities 50 to 70 %, fixed-income securities 30 to 50 %, alternative securities 0 to 15 %, and other cash equivalents 0 to 10 %. Based on changes in economic and market conditions, the Corporation could be outside of the allocation ranges for brief periods of time. The asset allocation for the RAP as of the December 31, 2023 and 2022 measurement dates, respectively, by asset category were as follows:
|
text
|
70
|
percentItemType
|
text: <entity> 70 </entity> <entity type> percentItemType </entity type> <context> The RAP’s investments are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risks associated with certain investments and the level of uncertainty related to changes in the value of the investments, it is at least reasonably possible that changes in risks in the near term could materially affect the amounts reported. The investment objective for the RAP is to ensure there are sufficient assets to pay pension obligations when they come due while mitigating risks and providing prudent governance. The RAP has a diversified portfolio designed to provide liquidity, current income, and growth of income and principal, with anticipated asset allocation ranges of: equity securities 50 to 70 %, fixed-income securities 30 to 50 %, alternative securities 0 to 15 %, and other cash equivalents 0 to 10 %. Based on changes in economic and market conditions, the Corporation could be outside of the allocation ranges for brief periods of time. The asset allocation for the RAP as of the December 31, 2023 and 2022 measurement dates, respectively, by asset category were as follows: </context>
|
us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
|
The RAP’s investments are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risks associated with certain investments and the level of uncertainty related to changes in the value of the investments, it is at least reasonably possible that changes in risks in the near term could materially affect the amounts reported. The investment objective for the RAP is to ensure there are sufficient assets to pay pension obligations when they come due while mitigating risks and providing prudent governance. The RAP has a diversified portfolio designed to provide liquidity, current income, and growth of income and principal, with anticipated asset allocation ranges of: equity securities 50 to 70 %, fixed-income securities 30 to 50 %, alternative securities 0 to 15 %, and other cash equivalents 0 to 10 %. Based on changes in economic and market conditions, the Corporation could be outside of the allocation ranges for brief periods of time. The asset allocation for the RAP as of the December 31, 2023 and 2022 measurement dates, respectively, by asset category were as follows:
|
text
|
30
|
percentItemType
|
text: <entity> 30 </entity> <entity type> percentItemType </entity type> <context> The RAP’s investments are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risks associated with certain investments and the level of uncertainty related to changes in the value of the investments, it is at least reasonably possible that changes in risks in the near term could materially affect the amounts reported. The investment objective for the RAP is to ensure there are sufficient assets to pay pension obligations when they come due while mitigating risks and providing prudent governance. The RAP has a diversified portfolio designed to provide liquidity, current income, and growth of income and principal, with anticipated asset allocation ranges of: equity securities 50 to 70 %, fixed-income securities 30 to 50 %, alternative securities 0 to 15 %, and other cash equivalents 0 to 10 %. Based on changes in economic and market conditions, the Corporation could be outside of the allocation ranges for brief periods of time. The asset allocation for the RAP as of the December 31, 2023 and 2022 measurement dates, respectively, by asset category were as follows: </context>
|
us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
|
The RAP’s investments are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risks associated with certain investments and the level of uncertainty related to changes in the value of the investments, it is at least reasonably possible that changes in risks in the near term could materially affect the amounts reported. The investment objective for the RAP is to ensure there are sufficient assets to pay pension obligations when they come due while mitigating risks and providing prudent governance. The RAP has a diversified portfolio designed to provide liquidity, current income, and growth of income and principal, with anticipated asset allocation ranges of: equity securities 50 to 70 %, fixed-income securities 30 to 50 %, alternative securities 0 to 15 %, and other cash equivalents 0 to 10 %. Based on changes in economic and market conditions, the Corporation could be outside of the allocation ranges for brief periods of time. The asset allocation for the RAP as of the December 31, 2023 and 2022 measurement dates, respectively, by asset category were as follows:
|
text
|
0
|
percentItemType
|
text: <entity> 0 </entity> <entity type> percentItemType </entity type> <context> The RAP’s investments are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risks associated with certain investments and the level of uncertainty related to changes in the value of the investments, it is at least reasonably possible that changes in risks in the near term could materially affect the amounts reported. The investment objective for the RAP is to ensure there are sufficient assets to pay pension obligations when they come due while mitigating risks and providing prudent governance. The RAP has a diversified portfolio designed to provide liquidity, current income, and growth of income and principal, with anticipated asset allocation ranges of: equity securities 50 to 70 %, fixed-income securities 30 to 50 %, alternative securities 0 to 15 %, and other cash equivalents 0 to 10 %. Based on changes in economic and market conditions, the Corporation could be outside of the allocation ranges for brief periods of time. The asset allocation for the RAP as of the December 31, 2023 and 2022 measurement dates, respectively, by asset category were as follows: </context>
|
us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
|
The RAP’s investments are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risks associated with certain investments and the level of uncertainty related to changes in the value of the investments, it is at least reasonably possible that changes in risks in the near term could materially affect the amounts reported. The investment objective for the RAP is to ensure there are sufficient assets to pay pension obligations when they come due while mitigating risks and providing prudent governance. The RAP has a diversified portfolio designed to provide liquidity, current income, and growth of income and principal, with anticipated asset allocation ranges of: equity securities 50 to 70 %, fixed-income securities 30 to 50 %, alternative securities 0 to 15 %, and other cash equivalents 0 to 10 %. Based on changes in economic and market conditions, the Corporation could be outside of the allocation ranges for brief periods of time. The asset allocation for the RAP as of the December 31, 2023 and 2022 measurement dates, respectively, by asset category were as follows:
|
text
|
15
|
percentItemType
|
text: <entity> 15 </entity> <entity type> percentItemType </entity type> <context> The RAP’s investments are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risks associated with certain investments and the level of uncertainty related to changes in the value of the investments, it is at least reasonably possible that changes in risks in the near term could materially affect the amounts reported. The investment objective for the RAP is to ensure there are sufficient assets to pay pension obligations when they come due while mitigating risks and providing prudent governance. The RAP has a diversified portfolio designed to provide liquidity, current income, and growth of income and principal, with anticipated asset allocation ranges of: equity securities 50 to 70 %, fixed-income securities 30 to 50 %, alternative securities 0 to 15 %, and other cash equivalents 0 to 10 %. Based on changes in economic and market conditions, the Corporation could be outside of the allocation ranges for brief periods of time. The asset allocation for the RAP as of the December 31, 2023 and 2022 measurement dates, respectively, by asset category were as follows: </context>
|
us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
|
The RAP’s investments are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risks associated with certain investments and the level of uncertainty related to changes in the value of the investments, it is at least reasonably possible that changes in risks in the near term could materially affect the amounts reported. The investment objective for the RAP is to ensure there are sufficient assets to pay pension obligations when they come due while mitigating risks and providing prudent governance. The RAP has a diversified portfolio designed to provide liquidity, current income, and growth of income and principal, with anticipated asset allocation ranges of: equity securities 50 to 70 %, fixed-income securities 30 to 50 %, alternative securities 0 to 15 %, and other cash equivalents 0 to 10 %. Based on changes in economic and market conditions, the Corporation could be outside of the allocation ranges for brief periods of time. The asset allocation for the RAP as of the December 31, 2023 and 2022 measurement dates, respectively, by asset category were as follows:
|
text
|
10
|
percentItemType
|
text: <entity> 10 </entity> <entity type> percentItemType </entity type> <context> The RAP’s investments are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risks associated with certain investments and the level of uncertainty related to changes in the value of the investments, it is at least reasonably possible that changes in risks in the near term could materially affect the amounts reported. The investment objective for the RAP is to ensure there are sufficient assets to pay pension obligations when they come due while mitigating risks and providing prudent governance. The RAP has a diversified portfolio designed to provide liquidity, current income, and growth of income and principal, with anticipated asset allocation ranges of: equity securities 50 to 70 %, fixed-income securities 30 to 50 %, alternative securities 0 to 15 %, and other cash equivalents 0 to 10 %. Based on changes in economic and market conditions, the Corporation could be outside of the allocation ranges for brief periods of time. The asset allocation for the RAP as of the December 31, 2023 and 2022 measurement dates, respectively, by asset category were as follows: </context>
|
us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
|
The health care trend rate is an assumption as to how much the Postretirement Plan’s medical costs will change each year in the future. There are no remaining participants under age 65 in the Postretirement Plan. The actual change in 2023 health care premium rates for post-65 coverage was an increase of 4.00 %. The health care trend rate assumption for post-65 coverage assumes a 5.00 % rate of increase for 2024 and future years.
|
text
|
5.00
|
percentItemType
|
text: <entity> 5.00 </entity> <entity type> percentItemType </entity type> <context> The health care trend rate is an assumption as to how much the Postretirement Plan’s medical costs will change each year in the future. There are no remaining participants under age 65 in the Postretirement Plan. The actual change in 2023 health care premium rates for post-65 coverage was an increase of 4.00 %. The health care trend rate assumption for post-65 coverage assumes a 5.00 % rate of increase for 2024 and future years. </context>
|
us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
|
The Corporation also has a 401(k) and Employee Stock Ownership Plan (the “401(k) plan”). The Corporation’s contribution is determined by the Compensation and Benefits Committee of the Board of Directors. Total expenses related to contributions to the 401(k) plan were $ 16 million, $ 15 million, and $ 13 million for 2023, 2022, and 2021, respectively.
|
text
|
16
|
monetaryItemType
|
text: <entity> 16 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation also has a 401(k) and Employee Stock Ownership Plan (the “401(k) plan”). The Corporation’s contribution is determined by the Compensation and Benefits Committee of the Board of Directors. Total expenses related to contributions to the 401(k) plan were $ 16 million, $ 15 million, and $ 13 million for 2023, 2022, and 2021, respectively. </context>
|
us-gaap:DefinedContributionPlanCostRecognized
|
The Corporation also has a 401(k) and Employee Stock Ownership Plan (the “401(k) plan”). The Corporation’s contribution is determined by the Compensation and Benefits Committee of the Board of Directors. Total expenses related to contributions to the 401(k) plan were $ 16 million, $ 15 million, and $ 13 million for 2023, 2022, and 2021, respectively.
|
text
|
15
|
monetaryItemType
|
text: <entity> 15 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation also has a 401(k) and Employee Stock Ownership Plan (the “401(k) plan”). The Corporation’s contribution is determined by the Compensation and Benefits Committee of the Board of Directors. Total expenses related to contributions to the 401(k) plan were $ 16 million, $ 15 million, and $ 13 million for 2023, 2022, and 2021, respectively. </context>
|
us-gaap:DefinedContributionPlanCostRecognized
|
The Corporation also has a 401(k) and Employee Stock Ownership Plan (the “401(k) plan”). The Corporation’s contribution is determined by the Compensation and Benefits Committee of the Board of Directors. Total expenses related to contributions to the 401(k) plan were $ 16 million, $ 15 million, and $ 13 million for 2023, 2022, and 2021, respectively.
|
text
|
13
|
monetaryItemType
|
text: <entity> 13 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation also has a 401(k) and Employee Stock Ownership Plan (the “401(k) plan”). The Corporation’s contribution is determined by the Compensation and Benefits Committee of the Board of Directors. Total expenses related to contributions to the 401(k) plan were $ 16 million, $ 15 million, and $ 13 million for 2023, 2022, and 2021, respectively. </context>
|
us-gaap:DefinedContributionPlanCostRecognized
|
At December 31, 2023, the Corporation had state net operating loss carryforwards of $ 126 million (of which $ 2 million was acquired from various acquisitions) that will begin expiring in 2024 .
|
text
|
126
|
monetaryItemType
|
text: <entity> 126 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2023, the Corporation had state net operating loss carryforwards of $ 126 million (of which $ 2 million was acquired from various acquisitions) that will begin expiring in 2024 . </context>
|
us-gaap:OperatingLossCarryforwards
|
The contract or notional amount of a derivative is used to determine, along with the other terms of the derivative, the amounts to be exchanged between the counterparties. The Corporation is exposed to credit risk in the event of nonperformance by counterparties to financial instruments. To mitigate the counterparty risk, contracts generally contain language outlining collateral pledging requirements for each counterparty. For non-centrally cleared derivatives, collateral must be posted when the market value exceeds certain mutually agreed upon threshold limits. Securities and cash are often pledged as collateral. The Corporation pledged $ 93 million and $ 92 million of investment securities as collateral at December 31, 2023, and 2022, respectively. Cash is often pledged as collateral for derivatives that are not centrally cleared. The Corporation's required cash
|
text
|
93
|
monetaryItemType
|
text: <entity> 93 </entity> <entity type> monetaryItemType </entity type> <context> The contract or notional amount of a derivative is used to determine, along with the other terms of the derivative, the amounts to be exchanged between the counterparties. The Corporation is exposed to credit risk in the event of nonperformance by counterparties to financial instruments. To mitigate the counterparty risk, contracts generally contain language outlining collateral pledging requirements for each counterparty. For non-centrally cleared derivatives, collateral must be posted when the market value exceeds certain mutually agreed upon threshold limits. Securities and cash are often pledged as collateral. The Corporation pledged $ 93 million and $ 92 million of investment securities as collateral at December 31, 2023, and 2022, respectively. Cash is often pledged as collateral for derivatives that are not centrally cleared. The Corporation's required cash </context>
|
us-gaap:AdditionalCollateralAggregateFairValue
|
The contract or notional amount of a derivative is used to determine, along with the other terms of the derivative, the amounts to be exchanged between the counterparties. The Corporation is exposed to credit risk in the event of nonperformance by counterparties to financial instruments. To mitigate the counterparty risk, contracts generally contain language outlining collateral pledging requirements for each counterparty. For non-centrally cleared derivatives, collateral must be posted when the market value exceeds certain mutually agreed upon threshold limits. Securities and cash are often pledged as collateral. The Corporation pledged $ 93 million and $ 92 million of investment securities as collateral at December 31, 2023, and 2022, respectively. Cash is often pledged as collateral for derivatives that are not centrally cleared. The Corporation's required cash
|
text
|
92
|
monetaryItemType
|
text: <entity> 92 </entity> <entity type> monetaryItemType </entity type> <context> The contract or notional amount of a derivative is used to determine, along with the other terms of the derivative, the amounts to be exchanged between the counterparties. The Corporation is exposed to credit risk in the event of nonperformance by counterparties to financial instruments. To mitigate the counterparty risk, contracts generally contain language outlining collateral pledging requirements for each counterparty. For non-centrally cleared derivatives, collateral must be posted when the market value exceeds certain mutually agreed upon threshold limits. Securities and cash are often pledged as collateral. The Corporation pledged $ 93 million and $ 92 million of investment securities as collateral at December 31, 2023, and 2022, respectively. Cash is often pledged as collateral for derivatives that are not centrally cleared. The Corporation's required cash </context>
|
us-gaap:AdditionalCollateralAggregateFairValue
|
collateral was $ 5 million at December 31, 2023, compared to $ 3 million at December 31, 2022. See Note 18 for fair value information and disclosures and see Note 1 for the Corporation's accounting policy for derivative and hedging activities.
|
text
|
5
|
monetaryItemType
|
text: <entity> 5 </entity> <entity type> monetaryItemType </entity type> <context> collateral was $ 5 million at December 31, 2023, compared to $ 3 million at December 31, 2022. See Note 18 for fair value information and disclosures and see Note 1 for the Corporation's accounting policy for derivative and hedging activities. </context>
|
us-gaap:DerivativeCollateralRightToReclaimCash
|
collateral was $ 5 million at December 31, 2023, compared to $ 3 million at December 31, 2022. See Note 18 for fair value information and disclosures and see Note 1 for the Corporation's accounting policy for derivative and hedging activities.
|
text
|
3
|
monetaryItemType
|
text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> collateral was $ 5 million at December 31, 2023, compared to $ 3 million at December 31, 2022. See Note 18 for fair value information and disclosures and see Note 1 for the Corporation's accounting policy for derivative and hedging activities. </context>
|
us-gaap:DerivativeCollateralRightToReclaimCash
|
The Corporation facilitates customer borrowing activity by entering into various derivative contracts which are designated as free standing derivative contracts. Free standing derivative products are entered into primarily for the benefit of commercial customers seeking to manage their exposures to interest rate risk, foreign currency, and until early 2022, commodity prices. As of the end of the first quarter of 2022, the Corporation no longer had any outstanding commodity contracts. These derivative contracts are not designated against specific assets and liabilities on the consolidated balance sheets or forecasted transactions and, therefore, do not qualify for hedge accounting treatment. Such derivative contracts are carried at fair value in other assets and accrued expenses and other liabilities on the consolidated balance sheets with changes in the fair value recorded as a component of capital markets, net, and typically include interest rate-related instruments (swaps and caps), foreign currency exchange forwards, and until the end of the first quarter of 2022, commodity contracts. See Note 15 for additional information and disclosures on balance sheet offsetting.
|
text
|
no
|
monetaryItemType
|
text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> The Corporation facilitates customer borrowing activity by entering into various derivative contracts which are designated as free standing derivative contracts. Free standing derivative products are entered into primarily for the benefit of commercial customers seeking to manage their exposures to interest rate risk, foreign currency, and until early 2022, commodity prices. As of the end of the first quarter of 2022, the Corporation no longer had any outstanding commodity contracts. These derivative contracts are not designated against specific assets and liabilities on the consolidated balance sheets or forecasted transactions and, therefore, do not qualify for hedge accounting treatment. Such derivative contracts are carried at fair value in other assets and accrued expenses and other liabilities on the consolidated balance sheets with changes in the fair value recorded as a component of capital markets, net, and typically include interest rate-related instruments (swaps and caps), foreign currency exchange forwards, and until the end of the first quarter of 2022, commodity contracts. See Note 15 for additional information and disclosures on balance sheet offsetting. </context>
|
us-gaap:DerivativeAssets
|
As of the end of the first quarter of 2022, the Corporation no longer had any outstanding commodity contracts. Historically, commodity contracts were entered into primarily for the benefit of commercial customers seeking to manage their exposure to fluctuating commodity prices. The Corporation mitigated its risk by then entering into an offsetting commodity derivative contract.
|
text
|
no
|
monetaryItemType
|
text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> As of the end of the first quarter of 2022, the Corporation no longer had any outstanding commodity contracts. Historically, commodity contracts were entered into primarily for the benefit of commercial customers seeking to manage their exposure to fluctuating commodity prices. The Corporation mitigated its risk by then entering into an offsetting commodity derivative contract. </context>
|
us-gaap:DerivativeAssets
|
The Corporation terminated its $ 500 million fair value hedge during the fourth quarter of 2019. At December 31, 2023, the amortized cost basis of the closed portfolios which had previously been used in the terminated hedging relationship was $ 267 million and is included in loans on the consolidated balance sheets. This amount includes $ 1 million of hedging adjustments on the discontinued hedging relationships, which are not presented in the table above.
|
text
|
1
|
monetaryItemType
|
text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> The Corporation terminated its $ 500 million fair value hedge during the fourth quarter of 2019. At December 31, 2023, the amortized cost basis of the closed portfolios which had previously been used in the terminated hedging relationship was $ 267 million and is included in loans on the consolidated balance sheets. This amount includes $ 1 million of hedging adjustments on the discontinued hedging relationships, which are not presented in the table above. </context>
|
us-gaap:DeferredGainLossOnDiscontinuationOfFairValueHedge
|
Amounts reported in accumulated other comprehensive income (loss) related to cash flow hedge derivatives are reclassified to interest income as interest payments are made on the hedged variable interest rate assets. The Corporation estimates that $ 7 million will be reclassified as a decrease to interest income over the next 12 months. This amount could differ from amounts actually recognized due to changes in interest rates, hedge de-designations, or the addition of other hedges subsequent to December 31, 2023. The maximum length of time over which the Corporation is hedging its exposure to the variability in future cash flows is 35 months as of December 31, 2023.
|
text
|
7
|
monetaryItemType
|
text: <entity> 7 </entity> <entity type> monetaryItemType </entity type> <context> Amounts reported in accumulated other comprehensive income (loss) related to cash flow hedge derivatives are reclassified to interest income as interest payments are made on the hedged variable interest rate assets. The Corporation estimates that $ 7 million will be reclassified as a decrease to interest income over the next 12 months. This amount could differ from amounts actually recognized due to changes in interest rates, hedge de-designations, or the addition of other hedges subsequent to December 31, 2023. The maximum length of time over which the Corporation is hedging its exposure to the variability in future cash flows is 35 months as of December 31, 2023. </context>
|
us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
|